Free Trial

Longeveron (LGVN) Competitors

Longeveron logo
$1.32 +0.01 (+0.38%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LGVN vs. VNRX, SRZN, EPIX, PLRX, MGNX, ZURA, ONCY, QNCX, PYXS, and BMEA

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), Pliant Therapeutics (PLRX), MacroGenics (MGNX), Zura Bio (ZURA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), Pyxis Oncology (PYXS), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

Longeveron vs. Its Competitors

Longeveron (NASDAQ:LGVN) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Longeveron has a net margin of -760.72% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-760.72% -85.07% -70.74%
VolitionRx -2,321.14%N/A -163.39%

Longeveron has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$2.39M8.21-$15.97M-$6.28-0.21
VolitionRx$1.31M54.63-$35.32M-$0.27-2.57

Longeveron has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Longeveron currently has a consensus target price of $8.67, indicating a potential upside of 559.06%. VolitionRx has a consensus target price of $3.50, indicating a potential upside of 404.47%. Given Longeveron's stronger consensus rating and higher probable upside, equities analysts plainly believe Longeveron is more favorable than VolitionRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
VolitionRx
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Longeveron's average media sentiment score of 0.00 equaled VolitionRx'saverage media sentiment score.

Company Overall Sentiment
Longeveron Neutral
VolitionRx Neutral

10.0% of Longeveron shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 11.2% of Longeveron shares are held by insiders. Comparatively, 10.4% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Longeveron beats VolitionRx on 10 of the 14 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

MetricLongeveronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.63M$2.85B$5.45B$8.92B
Dividend YieldN/A2.44%5.22%4.00%
P/E Ratio-0.2120.6327.2720.07
Price / Sales8.21290.56428.46118.22
Price / CashN/A41.7026.2128.59
Price / Book0.897.427.925.58
Net Income-$15.97M-$55.04M$3.17B$248.65M
7 Day Performance1.15%3.70%4.33%7.15%
1 Month Performance6.91%0.35%2.61%8.13%
1 Year Performance-23.99%4.79%34.78%21.59%

Longeveron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
3.3109 of 5 stars
$1.32
+0.4%
$8.67
+559.1%
-24.0%$19.63M$2.39M-0.2120
VNRX
VolitionRx
1.6677 of 5 stars
$0.76
-9.3%
$3.50
+360.5%
+27.4%$78.30M$1.31M-2.1180Gap Down
SRZN
Surrozen
2.3613 of 5 stars
$8.94
-0.9%
$38.50
+330.6%
-9.7%$77.24M$10.65M-0.3680Positive News
High Trading Volume
EPIX
ESSA Pharma
1.2828 of 5 stars
$1.70
-1.7%
$2.00
+17.6%
-65.4%$76.79MN/A-2.7050Positive News
PLRX
Pliant Therapeutics
3.9731 of 5 stars
$1.16
-7.2%
$13.31
+1,047.6%
-88.2%$76.73M$1.58M-0.3290High Trading Volume
MGNX
MacroGenics
4.1111 of 5 stars
$1.21
+1.7%
$5.71
+372.3%
-65.7%$75.08M$149.96M-1.36430Gap Up
ZURA
Zura Bio
3.5019 of 5 stars
$1.05
flat
$14.33
+1,265.1%
-67.5%$71.79MN/A-1.503Positive News
Gap Up
ONCY
Oncolytics Biotech
1.6659 of 5 stars
$0.77
+3.0%
$4.33
+460.6%
-12.5%$70.77MN/A-2.6730Gap Down
QNCX
Quince Therapeutics
2.8921 of 5 stars
$1.65
+6.5%
$8.00
+384.8%
+120.1%$70.48MN/A-1.1960
PYXS
Pyxis Oncology
1.2151 of 5 stars
$1.10
flat
$9.00
+718.2%
-61.6%$68.14M$16.15M-0.6960Positive News
BMEA
Biomea Fusion
2.5595 of 5 stars
$1.80
-0.6%
$21.40
+1,088.9%
-60.9%$68.01MN/A-0.5150

Related Companies and Tools


This page (NASDAQ:LGVN) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners